April 19, 2022 – The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, and Matrix Clinical Trials, a Matrix Medical Network offering, are collaborating to bring clinical trials to patients with an innovative decentralized clinical trial (DCT) solution. The business is deploying state-of-the-art Matrix mobile research sites and expert clinical staff across the U.S. to help identify, recruit and retain trial participants, while ensuring a positive patient experience. At the same time, the two companies are exploring opportunities to expand the collaboration to additional geographies.
Thermo Fisher’s clinical research business is the only clinical research organization (CRO) to use Matrix’s virtual principal investigator network coupled with mobile sites as a stand-alone transportable clinical trial operation. The collaboration demonstrates Thermo Fisher’s continuing commitment to advance decentralized trial solutions for customers and patients.
“We are proud to be a source for one of the latest clinical innovations to enhance patient-centric trial participation,” said Tim Rich, vice president, digital and decentralized solutions, clinical research, Thermo Fisher. “Mobile sites are a key component of our sought-after portfolio of hybrid and decentralized clinical trial capabilities. With Matrix’s experienced teams of clinicians and ready-to-deploy mobile sites, we are able to reach a broader range of participants, including in previously under-represented and under-served communities, without requiring them to travel to traditional investigator sites far from their homes.”
Thermo Fisher’s clinical research business provides flexible decentralized trial solutions developed across multiple therapeutic areas. The goal is to increase patient diversity and access, and to improve the patient experience, resulting in time efficiencies and data quality enhancements that can help speed development timelines. These services reduce the burden for patients to participate in clinical trials, while providing customers with greater geographic reach through reduced reliance on brick-and-mortar site locations, more timely access to data, improved quality and consistency, and better patient engagement.